Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases — alphai